A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Chemotherapy-induced Nausea and Vomiting
Interventions: DRUG: fosnetupitant/ palonosetron|DRUG: netupitant/palonosetron|DRUG: dexamethasone
Sponsor: Helsinn Healthcare SA
Collaborators: George Clinical Pty Ltd|The Physicians' Services Incorporated Foundation